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Abstract The introduction of kinase inhibitors in cancer
medicine has transformed chronic myeloid leukemia from
a fatal disease into a leukemia subtype with a favorable
prognosis by interfering with the constitutively active
kinase BCR-ABL. This success story has resulted in the
development of multiple kinase inhibitors. We are cur-
rently facing significant limitations in implementing these
kinase inhibitors into the clinic for the treatment of pedi-
atric malignancies. As many hallmarks of cancer are
known to be regulated by intracellular protein signaling
networks, we suggest focusing on these networks to
improve the implementation of kinase inhibitors. This
viewpoint will provide a short overview of currently used
strategies for the implementation of kinase inhibitors as
well as reasons why kinase inhibitors have unfortunately
not yet been widely used for the treatment of pediatric
cancers. We argue that by using a future personalized
medicine strategy combining kinomics, proteomics, and
drug screen approaches, the gap between pediatric cancers
and the use of kinase inhibitors may be bridged.
Keywords Targeted therapy  Kinomics  Proteomics 
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Introduction
Cancer is the second most common cause of death among
children living in developed countries [1]. The current
incidence of childhood cancers is 189.5 per million chil-
dren and this incidence is increasing with approximately
0.6 % each year [1]. Although the 5-year overall survival
rates range around 80 %, every year nearly 2000 children
die due to cancer in the United States of America [1].
The introduction of chemotherapy for childhood leuke-
mia in the beginning of the 1950s was a remarkable
improvement for cancer research [2]. However, it took
until 1963 and early 1970 before the first patients with
acute childhood leukemia and advanced Hodgkin’s lym-
phoma were cured using a combination of
chemotherapeutics [2]. The observed major improvements
in outcome obtained over the past few decades, achieved
by dose optimization and combination chemotherapy, are
nowadays stagnated due to chemotherapy-related toxicity
[3]. With the introduction of tyrosine kinase inhibitors
(TKIs), like imatinib (Gleevec), a new era of cancer
therapy emerged. Imatinib transformed chronic myeloid
leukemia (CML) from a fatal disease to a leukemic subtype
with a favorable prognosis [4]. During the last decade, a
rapid increase in the development of small molecule inhi-
bitors and monoclonal antibodies enabled the availability
for therapeutic intervention. In 2014, the US Food and
Drug administration (FDA) approved 41 new drugs, of
which two were protein kinase inhibitors for cancer indi-
cations (e.g., iselalisib and ceritinib, Table 1). Today, 29
protein kinase inhibitors are FDA-approved for the treat-
ment of cancer (Table 1). Remarkably, the main targets of
these approved protein kinase inhibitors are limited to the
BCR-ABL kinase (six inhibitors), members of the ErbB-
family receptor tyrosine kinases, especially EGFR (five
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inhibitors), the ALK kinase (two inhibitors), and the BRAF
kinase (four inhibitors), all frequently mutated in types of
adult-onset cancer [4–7].
Protein kinase inhibitors suppress the activity of kinases,
enzymes catalyzing protein phosphorylation by transferring
phosphate groups from adenosine triphosphate (ATP) to
specific proteins. Protein kinases are attractive targets for
cancer therapy, as the malignant transformation of cells
highly depends on deregulated kinase-mediated signal
transduction pathways; intracellular signaling cascades
involving protein phosphorylation events regulating critical
cellular processes [8, 9].
Focusing on FDA-approved protein kinase inhibitors for
children revealed an approval of only three inhibitors
(Table 1). To date, several drugs that have been approved
for the treatment of adult malignancies are often only
prescribed off-label for the treatment of pediatric cancer
patients. However, the extrapolation of clinical trial results
obtained from treating adult patients towards pediatric
cancer patients is often inappropriate [10]. First, malig-
nancies in children are different compared to adult
malignancies [10]. Secondly, medications metabolize dif-
ferently in children compared to adults, resulting in
unpredictable treatment responses and side effects in chil-
dren [10]. Pediatric drug testing is problematic for a
number of reasons. Clinical trials in children are restricted
to diseased children for whom a minimal benefit of par-
ticipating in the clinical trial should be achieved.
Furthermore, in contrast to trial participation in adults,
parents and pediatricians are usually more concerned about
the risks and benefits for the individual child [10]. The
most important reason why clinical trials in children have
been hampered is the limited number of patients eligible
for clinical trials, since pediatric cancer is relatively rare.
Moreover, as a consequence of these low patient numbers,
the pharmaceutical industry is less interested in funding
clinical trials in children since pediatric clinical trials are
costly and the financial profit is minimal [10]. Nonetheless,
we have to prevent that ineffective and potentially harmful
interventions are subjected to pediatric oncology patients
before they have been properly tested.
To improve pediatric medicine, pediatric regulations
came into force in the European Union in 2007 and the
Pediatric Investigation Plan (PIP) was launched; a research
and development program aimed at ensuring the generation
of data required to determine the conditions in which a
compound may be authorized to treat the pediatric popu-
lation [11, 12]. As a reward for participating in the PIP,
pharmaceutical companies gain patent extension. The
introduction of these regulations has resulted in more
pediatric clinical trials, an increase in available drugs
authorized for pediatric indications, and prevented that
children are subjected to unnecessary studies [11, 12].
Nevertheless, still only three protein kinase inhibitors are
approved for the treatment of pediatric malignancies.
To summarize the current problem, on the one hand we
have a multitude of small molecule inhibitors including
protein kinase inhibitors (either FDA approved or still in
the pipelines of pharmaceutical companies), and on the
other hand we have a number of children with untreatable
cancer. Since we face limitations implementing these
kinase inhibitors for the treatment of pediatric malignan-
cies, many potentially useful drugs remain unused. This
viewpoint will provide (1) a short overview of study
strategies, including genome and transcriptome profiling,
kinome and proteome profiling, and drug screen approa-
ches currently used to gain insight into intracellular
signaling networks that are of potential interest for the
introduction of new treatment options, and (2) highlights
the reasons why kinase inhibitors are unfortunately not
commonly used for the treatment of pediatric cancer.
Lastly, we will propose a personalized medicine strategy
by combining kinomics, proteomics, and drug screens
aiming to bridge the gap between pediatric cancers and the
use of kinase inhibitors.
Hallmarks of cancer
Cancer can arise in different organs, tissues, and cell types,
all with a distinct disease presentation and outcome. Sev-
eral characteristics are shared throughout different cancers.
These characteristics, or key hallmarks of cancer, were
established by Hanahan and Weinberg presenting the
complexity and capabilities of cancer cells [13, 14]. The
hallmarks of cancer comprise: sustaining proliferative
signaling, evading growth suppressors, resisting cell death,
enabling replicative immortality, inducing angiogenesis,
activating invasion and metastasis, avoiding immune
destruction, tumor-promoting inflammation, genome
instability and mutation, and deregulating cellular ener-
getics. These diverse processes have in common that they
provide a growth advantage of the cancer cell compared to
its normal counterpart. Recent technologies such as gen-
ome-wide genetic and transcriptional analysis using next-
generation sequencing revealed the mutational landscape
of many adult and pediatric cancers [15–18]. These thor-
ough analyses led to the discovery that, in general,
pediatric cancers exhibit fewer mutations than adult can-
cers, and that within specific types of cancer there is a high
variability of the mutations present [15]. This knowledge
leaves us with the thought that CML, harboring one unique
and uniform driver mutation (namely, BCR-ABL), is in fact
an exceptional situation. In other malignancies, the
pathobiology is more complex. For example, despite
intensive genome and transcriptome profiling, the majority
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of the pediatric acute lymphoblastic leukemia (ALL) cases
remain without explanation of precise genetic etiology
[18]. Therefore, the question must be asked; how can we
bridge the gap from insights in the hallmarks of cancer to
the use of available kinase inhibitors that are on the
market?
In addition to genetic alterations, epigenetic alterations
and the influence of microenvironmental factors can con-
tribute to oncogenesis and disease progression. Many of
these alterations ultimately support somatic cells to escape
the restraints that normally withhold them from unlimited
cell proliferation. This growth advantage is the net result of
aberrant activated signal transduction pathways [8]. Within
cancer cells, the above-mentioned hallmark capabilities are
regulated by highly interconnected intracellular signaling
networks [14]. Therefore, to understand how specific
kinase inhibitors may affect cancer hallmarks, more
insights into the key proteins within the intracellular sig-
naling networks to which these drugs can counteract are
needed. Currently, many recent studies focus on generating
insights into signal transduction networks as a final com-
mon pathway of various cancer hallmarks that are
translated into cancer cell progression.
Short overview of strategies used
for the identification of treatment options
Genome and transcriptome profiling
In the last decade, genome and transcriptome sequencing
have improved our understanding of human cancers sig-
nificantly [15, 19]. These cancer studies have revealed a set
of 138 genes that, when altered by mutations, can promote
oncogenesis [15]. Additionally, mutations can be theoreti-
cally distinguished in ‘‘driving mutations’’, mutations that
confer a selective growth advantage, or ‘‘passenger muta-
tions’’, mutations that have no effect on neoplastic
processes [15]. In practice, it is difficult to determine which
mutations drive oncogenesis and/or contribute to malignant
transformation or progression [15]. This is partially due to
the fact that some mutations require collaborative muta-
tions to enable oncogenic transformation. Importantly,
comprehensive sequencing efforts have revealed genetic
alterations that are now being treated with specific kinase
inhibitors. This started with BCR-ABL inhibitors for the
treatment of CML and has continued with, for example,
ALK translocations and EGFR mutations in non-small-cell
lung cancer and BRAF mutations in melanoma (Table 1),
as well as genetic alterations currently tested in clinical
trials such as FLT3-ITD and JAK mutations in pediatric
leukemias [20–22]. Unfortunately, although genome and
transcriptome profiling has increased our understanding of
oncogenesis and improved outcome for several malignan-
cies, there are still malignancies, especially in children, in
which the oncogenic alterations that drive cancer progres-
sion are largely unknown. Consequently, kinase inhibitors
directed to specific driving mutations cannot be used for
the treatment of most pediatric malignancies. Moreover,
the combination of gene expression signatures and anti-
cancer drug sensitivity patterns provided inconsistent
results. While some cancers with known mutations
expected to be sensitive towards specific inhibitors proved
indeed to be highly sensitive, in other cancers, harboring
the same mutation, specific inhibitors presented minor
anticancer responses or respond only for a short period of
time [23–25]. Additionally, the group of Clevers recently
showed a gene-drug association of only *1 % between
individual oncogenic mutations and drug response in adult
colorectal carcinoma patients [26]. Therefore, additional
study strategies are required for the identification of suit-
able targets for therapy.
Kinome and proteome profiling
As genetic and epigenetic alterations and/or microenvi-
ronmental factors ultimately influence the activation of
intracellular signaling networks, insight into these intra-
cellular signaling pathways might be a potent strategy for
identifying targetable signaling hubs for the treatment with
kinase inhibitors (Fig. 1) [8]. Current techniques to study
protein phosphorylation include for example high-
throughput techniques as reverse phase protein arrays
(RPPA), more intensive analysis by mass-spectrometry, or
single cell probe-based flow cytometry. Additionally, the
activity of kinases might be studied by for example high-
throughput peptide-based kinase activity arrays [27]. We
recently provided an extensive overview of the pros and
cons for different proteomic techniques that aim to assess
protein kinase activation and protein phosphorylation [27].
Elucidating signaling networks to identify suitable targets
for therapy might be valuable particularly for children
since pediatric cancers harbor fewer mutations compared to
adult cancers [15]. In recent years, our lab focused on using
comprehensive kinome and proteome profiling to identify
signaling networks as well as potential druggable targets
for various pediatric malignancies [28–30]. These studies
showed that kinome profiling is an elegant approach for
identifying therapeutic targets by elucidating signaling
pathways for common pediatric cancers, e.g., leukemias
[ALL and acute myeloid leukemia (AML)] and brain
tumors [28–30]. For example, kinome and proteome pro-
filing revealed c-AMP-responsive element binding protein
(CREB) activity in pediatric ALL, MEK activation in
pediatric MLL-rearranged AML, Src activity in pediatric
brain tumors, and a role for Eph/ephrin signaling in
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pediatric medulloblastoma [28, 29, 31, 32]. All these
findings were validated using in vitro cytotoxicity screens
that confirmed their potential as a therapeutic target [28,
29, 31, 32]. More importantly, we showed that the com-
bination of kinome and proteome profiling is a powerful
prediction approach for signaling pathway adaptations and
redundant pathway discovery upon single targeted therapy
and can be used to define rational combination therapies
[29]. For example, this approach revealed activity of the
MAPK and PI3K/Akt/mTOR signaling pathways in pedi-
atric MLL-rearranged AML and predicted that a sustained
PI3K/Akt/mTOR pathway activation enabled a subpopu-
lation of cells to survive MEK inhibition [29].
Drug screen approaches
Drug screening and genetic knockdown approaches, such
as high-throughput RNAi and kinase inhibitor screens,
have been used to define kinase pathway dependence [33–
37]. These strategies created patient-specific in vitro sen-
sitivity profiles against specific kinase targets by treating
adult primary leukemia cells with siRNA or kinase inhi-
bitors [35, 37]. Two important conclusions could be drawn
based upon these results, namely (1) there is a great
heterogeneity in predicted kinase targets between patients,
even within similar diagnostic subgroups, and (2) the
oncogenic mechanism for predicted therapeutic targets
could not be elucidated based upon underlying genomic
alterations [33, 35]. For example, gene silencing identified
an upregulation of receptor tyrosine kinase-like orphan
(RO)R1 expression in t(1;19)-positive pediatric ALL
patients, a mechanism based on pre-B cell receptor sig-
naling inhibition rather than ROR1 activating mutations or
aberrant transcription profiles [38]. Most importantly, drug
screens showed that targeting intracellular signaling path-
ways is a feasible therapeutic option.
As a proof of concept, Tyner and Pemovska used the
results from their drug screen to treat adult leukemia
patients not eligible to standard treatment options using
FDA-approved kinase inhibitors (n = 1 and n = 8,
respectively) [35, 37]. The initial results were very
promising, showing rapid decreases in white blood cell
counts and bone marrow blast counts in the majority of the
patients. However, effects were only short lasting; within
months patients relapsed after personalized kinase inhibitor
treatment [35, 37]. Repeated drug screens, of the relapsed
leukemia samples, showed resistance to the initially used
kinase inhibitors as compared to their corresponding pre-
treatment samples [35, 37]. These examples illustrate why
most long-term clinical results of kinase inhibitors are
disappointing when using monotherapy [39]. Innate or
acquired cellular resistance to kinase inhibitors are a major
clinical challenge [24, 35, 37, 40].
Resistance to kinase inhibitors
Several mechanisms of cancer cell resistance to kinase
inhibitors have been described. First of all, advanced
alterations in the present mutation, for example new kinase
domain mutations, confer resistance to kinase inhibitors by
decreasing the efficiency of the inhibitor [41]. A classic
example is BCR-ABL1 kinase domain mutations decreasing
the sensitivity to imatinib in CML [42].
Secondly, newly acquired alterations might circumvent
the inhibitory effect of a given drug; for instance, the
accumulation of various new genetic abnormalities in
CML result in the activation of signaling pathways
independent of BCR-ABL activity and consequently
facilitates disease progression to blast crisis [41, 43, 44].
Similarly, mutations in MEK1 can confer resistance to
BRAF inhibition [45].
Fig. 1 An illustration of why
insight into intracellular
signaling pathways might be a
potent strategy for bridging the
gap between pediatric
malignancies and the use of
available kinase inhibitors
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Thirdly, therapy resistance can be mediated by cellular
adaptations through dynamic reprogramming, e.g., the
activation of alternated routes of kinase pathway activation
in response to pharmacological inhibition [46]. Cellular
adaptation by dynamic reprogramming is an important
challenge for the implementation of kinase inhibitors and
Fig. 2 Visualization of a future
personalized medicine strategy
attempting to improve the
implementation of kinase
inhibitors in pediatric cancer.
After initial tumor
characterization, we propose to
perform kinome and proteome
profiling on patient samples, as
well as subject patient cells to a
drug screen including multiple
kinase inhibitors (either FDA




Integrating these results will
define rational combination
therapies. To determine
treatment effects on signaling,
kinome and proteome profiles
will be re-determined after
in vitro treatment with potential
combination therapies.
Ultimately, data integration of
all these multilevel study
elements will result in a
comprehensive network of pre-
treatment active signaling
pathways, putative targets for
targeted therapy, and
subsequent post-treatment drug-
induced bypass mechanisms for
cellular resistance
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can occur by either the reactivation of the targeted pathway
or via bypass opportunities through the activation of
alternative signaling pathways [41, 46]. An example of
reactivation of the targeted pathway is B-RAF (V600E)-
positive melanoma [47]. These cells can acquire resistance
to vemurafenib by reactivating the MAPK pathway via
N-RAS upregulation. Dynamic reprogramming might also
result in the activation of alternative signaling pathways;
for instance, by the upregulation of RTK-ligand levels that
has been frequently observed following kinase inhibition
and is able to activate downstream highly interconnected
intracellular signaling pathways, most notably the PI3K/
Akt/mTOR or MAPK signaling networks [40, 46]. In
addition, resistance to the BRAF inhibitor in colorectal
carcinoma might be due to the activation of the PI3K/Akt/
mTOR signaling pathway [48].
Finally, intratumor heterogeneity can also restrict the
implementation of targeted therapy. Intratumor hetero-
geneity may lead to inferior therapeutic responses to kinase
inhibitors since it has been established that the outgrowth
of a therapy-resistant subclone(s) can lead to refractory or
relapsed disease [41].
Future strategy for clinical trials in pediatric
oncology
Taken together, this viewpoint has highlighted currently
used strategies for the implementation of kinase inhibitors
as well as reasons why kinase inhibitors have unfortunately
not yet been widely used in pediatric cancer therapy. In this
paragraph, we will propose a personalized medicine strat-
egy attempting to improve the implementation of kinase
inhibitors in pediatric cancer.
We argue that establishing the active intracellular sig-
naling pathway networks in cancer patient samples will be
a suitable strategy in deciding which kinase inhibitors
(either FDA approved or in the pipelines of pharmaceutical
companies) should be used to target the cancer cell
(Fig. 1). As previously mentioned, drug screens have ini-
tially showed promising short-term results towards this end
[33–37]. Further, we have demonstrated that kinome and
proteome profiling is an elegant approach for identifying
potential druggable targets in pediatric malignancies [28–
30]. Additionally, we showed that this strategy is able to
predict signaling pathway adaptations that can be used to
define rational combination therapies, as shown for com-
bined MEK and VEGFR-2 inhibition in pediatric MLL-
rearranged AML [29]. Combining these kinomics and
proteomics study approaches with a comprehensive drug
screen can define major contributing protein kinases rele-
vant for cancer cell survival (Fig. 2). Following upon
initial tumor characterization, we propose to perform
kinome and proteome profiling to determine networks of
active signaling pathways, which enables to extract key
signaling hubs and also provides insight into how to predict
possible cancer cell bypass mechanisms based upon sig-
naling availability. Additionally, cancer cells will be
subjected to a drug screen containing drugs in current use
for cancer treatment, drugs previously investigated in or
currently undergoing clinical trials, and experimental
compounds to characterize cancer cell-specific drug sen-
sitivity patterns. While drug screens are relatively easy to
perform for hematological malignancies, the implementa-
tion of drug screens for solid tumors is more challenging—
but not impossible. Recently, it has been shown that an
organoid culture platform can be used for functional drug
screening assays of solid cancers [26]. This model also
reflects the polyclonality of tumors enabling a suitable
predictive model to define cytotoxic responses to therapy at
the level of the individual patient [26]. Integrating the
kinome and proteome profiles together with drug sensi-
tivity profiles into one network will generate an overview
of highly active signaling pathways including the corre-
sponding putative novel targets for therapy (highlighted in
the network, Fig. 2). Based on this network, rational
combination therapies could be defined by selecting suit-
able targets from different signaling pathways.
Since cellular dynamic reprogramming and intratumor
heterogeneity are major challenges for the implementation
of kinase inhibitors, insight into the adaptive kinome
responses and subclonal resistance to kinase inhibitors is
essential. By doing so, one can anticipate on mechanisms
of resistance. As it has been shown that redundant signaling
pathways as well as signaling profiles of minor subclones
are not per se detectable at the time of diagnosis and might
become more prominent after treatment with specific
kinase inhibitors, it will be necessary to re-determine cel-
lular dynamics of signaling pathway activation after
in vitro treatment with selected combination therapies
(Fig. 2). This second network analysis of signaling path-
ways might reveal cellular adaptations by activating
signaling events that can facilitate therapeutic resistance.
Integration of all these multilevel study elements will
generate a comprehensive network of pre-treatment active
signaling pathways, putative targets for targeted therapy,
and subsequent post-treatment drug-induced bypass
mechanisms for cellular resistance. If necessary, the initial
selected combination therapies can be modified to cir-
cumvent drug-induced bypass signaling pathways and to
select an optimal therapeutic strategy in advance. Extrap-
olation of this proposed in vitro model to an in vivo model
increases the translational feasibility of the preclinical
treatment screening, which is highly desirable since only
5 % of the identified putative anticancer compounds pre-
sent sufficient clinical activity in phase III trials [49, 50]. In
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the meantime, optimization of in vitro models, for example
by tumor organoid cultures, is of great importance to
improve preclinical models for drug testing.
One additional problem that we have to overcome is the
low number of pediatric patients eligible for clinical trials.
We have noticed an overlap of recurrent active signal
transduction pathways within different subtypes of cancer
[28–30]. Furthermore, the kinase inhibitor screen of Tyner
et al. showed no complete segregation based upon leuke-
mia subtypes [35]. Therefore, we propose that all children
suffering from cancer without evidence-based treatment
options are eligible to enroll in this study strategy. Com-
bining different patient populations allows studying the
mechanism of signal transduction adaptations and the
rational design of combination therapies in a significant
larger cohort of children. More importantly, a trial
including children with comparable signaling dynamics
will provide information about the optimal biological dose
for the kinase inhibitor; the dose that produces a quantifi-
able effect in inhibiting the target in the cancer cells
(primary endpoint). Additionally, pharmacokinetics, phar-
macodynamics, side effects, and toxicity spectrum of the
specific inhibitor in pediatric oncology patients should be
included as important objectives. Moreover, while the
primary objective of the proposed study design is bridging
the gap between pediatric cancers and newly designed
kinase inhibitors to the improve survival of children
without evidence-based treatment options, consequent
studies regarding the long-term effects of kinase inhibitors
on energy metabolism, growth and bone mineral density,
gonadal function and reproduction, and cardiac health are
warranted.
Finally, since the continuous development of new study
approaches is essential for the implementation of targeted
therapies, we expect that the proposed pre-clinical
screening strategy should incorporate additional novel
methods according to new developments. This integrated
multilevel screen might easily be developed further to an
integrated model of genome, kinome, and proteome pro-
filing, supported with networks of cell–cell and cell–stroma
interactions. In conclusion, despite initial disappointing
results of kinase inhibitors in clinical trials, we propose that
available kinase inhibitors holds tremendous promise for
most malignancies when using novel selective combina-
tions of therapeutic interventions. In this viewpoint, we
illustrate a personalized medicine strategy combining
kinomics and proteomics approaches with a comprehensive
drug screen to define rational combination therapies that
may bridge the gap between pediatric cancers and the
implementation of kinase inhibitors.
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